MedTrace Logo

Effects of Ivabradine on Residual Myocardial Ischemia After PCI

NCT03866395 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-03-07

No results posted yet for this study

Summary

This is a randomized pharmacological study evaluating the effects of ivabradine in patients with residual angina after PCI. The role of ivabradine in patients with angina, without systolic dysfunction, is not yet clear. The investigators performed in all patients an echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of exercise tolerance and diastolic function.

Conditions

  • Angina Pectoris, Stable

Interventions

DRUG

Ivabradine

Ivabradine 5 mg twice a day

Sponsors & Collaborators

  • Azienda Policlinico Umberto I

    lead OTHER

Principal Investigators

  • Massimo Mancone · Department of Cardiovascular disease, Sapienza, University of Rome, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-05
Primary Completion
2017-03-07
Completion
2017-03-07

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03866395 on ClinicalTrials.gov